에 대한 최신 뉴스 Verve Therapeutics (NASDAQ:VERV) 주식

Verve Therapeutics

Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.

Equities

News

Markets

ETFs

ACHR

ARKK

AVAV

BLDE

NTLA

TDOC

TSLA

VERV

수요일에 캐시 우드가 이끄는 아크 인베스트(Ark Invest)는 이 회사의 인상적인 2분기 납품 실적에 힘입은 최근 상승세에도 불구하고 테슬라(NASDAQ:TSLA)의 상당 수의 주식을 매각하여 주목할만한 움직임을 보였다.

아크 인베스트가 예상을 넘는 2분기 배송 실적에도 $3.25백만 규모 테슬라 주식 매도 추가

$BTC

ABSI

ARKW

COIN

ROKU

월요일에는 캐시 우드가 주도하는 아크 인베스트(Ark Invest)가 몇 가지 중요한 거래를 했으며, 그 가운데 코인베이스 글로벌(NASDAQ:COIN)의 거래가 주목을 받았다. 이는 특히 암호화폐의 경우 격동적인 시장 시나리오 속에서 발생했다.
코인 거래

아크 인베스트는 비트코인이 $62,000 아래로 하락하면서 코인베이스 주식을 매도

$ETH

ARCT

ARKF

ARKG

ARKQ

ARKX

HOOD

MKFG

캐시 우드가 이끄는 아크 인베스트(Ark Invest)는 수요일에 로빈후드 마켓(NASDAQ:HOOD) 및 줌 비디오 커뮤니케이션(NASDAQ:ZM)괴 관련하여 상당한 거래를 했다.
로빈후드 주식의 거래

아크 인베스트는 로빈후드 주식 150만 달러를 매도하며, 줌 주식 330만 달러 상당도 처분

Verve Therapeutics Inc

MGI MEDIA & GAMES INVEST by MGI MEDIA & GAMES INVEST SE

Verve Group SE

ARWR

GWRE

Guidewire Software To Replace Arrowhead Pharmaceuticals In S&P MidCap 400, Effective Prior To Opening Of Trading On January 27

Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) has outperformed the market over the past 10 years by 5.83% on an annualized basis producing an average annual return of 17.41%. Currently, Caterpillar has a market capitalization of $193.28 billion. 
Buying $100 In CAT: If an investor had bought $100 of CAT stock 10 years ago, it would be worth $462.18 today based on a price of $395.21 for CAT at the time of writing.
<h3>Caterpillar's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737584114_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In Caterpillar 10 Years Ago Would Be Worth This Much Today

The Notice has no immediate effect on the listing or trading of the Company's common stock on the Nasdaq Capital Market. However, if the Company fails to timely regain compliance with the Listing Rule, the Company's common stock will be subject to delisting from Nasdaq.

MULN

Mullen Receives Notice From Nasdaq Listing Qualifications Staff About Delayed Filing Of Annual Report

WIIM

TLSA

Tiziana Life Sciences shares are trading higher after the company announced the discovery of new immune biomarkets in its na-SPMS patients when treated with nasal foralumab.

Alcoa Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>) reported its fourth-quarter financial results after Wednesday's closing bell. Here's a look at the key <a href="https://www.benzinga.com/pressreleases/25/01/b43144306/alcoa-corporation-reports-fourth-quarter-and-full-year-2024-results">figures from the quarter. </a>
The Details: Alcoa reported quarterly earnings of $1.04 per share, which beat the analyst consensus estimate of 97 cents. Quarterly revenue clocked in at $3.48 billion, which beat the analyst consensus estimate of $3.33 billion and is an increase over sales of $2.59 billion from the same period last year.
Alumina production decreased two percent sequentially to 2.39 million metric tons. In the Aluminum segment, production increased two percent sequentially to 571,000 metric tons primarily due to continued progress on the Alumar, Brazil smelter restart.
In the Alumina segment, third-party revenue increased 46% due to an increase in average realized third-party price and higher shipments. In the Aluminum segment, third-party revenue increased 5% due to an increase in average realized third-party price.
Read Next: <a href="https://www.benzinga.com/news/large-cap/25/01/43106379/trump-reverses-bidens-ai-policies-on-day-1-what-it-means-for-tech-giants-nvidia-amd-alphabet">Trump Reverses Biden&#8217;s AI Policies On Day 1: What It Means For Tech Giants Nvidia, AMD, Alphabet&nbsp;</a>
&#8220;Reflecting on 2024, it was a productive year for Alcoa as we delivered on strategic actions and operational improvements, including closing the acquisition of Alumina Limited, announcing the sale of our interest in the Ma&#8217;aden joint ventures, hitting production records and improving operational stability,&#8221; said Alcoa president and CEO William F. Oplinger.&nbsp;
Outlook:&nbsp;Alcoa said it expects 2025 total Alumina segment production to range between 9.5 to 9.7 million metric tons, a decrease from 2024 due to the curtailment of the Kwinana refinery.
Alcoa expects 2025 total Aluminum segment production to range between 2.3 and 2.5 million metric tons, an increase from 2024 due to smelter restarts. 
AA Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Alcoa shares are up 0.41% after-hours at $38.94 Wednesday. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/initiation/25/01/43102452/roku-analyst-sees-25-upside-as-tv-ad-dollars-go-digital">Roku Analyst Sees 25% Upside As TV Ad Dollars Go Digital&nbsp;</a></li>
</ul>
Photo: Shutterstock

Earnings

Commodities

Global

After-Hours Center

Movers

Alcoa Shares Climb After Better-Than-Expected Q4 Results

First Internet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBK#NASDAQ">INBK</a>) reported quarterly earnings of $0.41 per share. This is a 14.58 percent decrease over earnings of $0.48 per share from the same period last year. The company reported quarterly sales of $39.487 million which beat the analyst consensus estimate of $24.332 million by 62.29 percent. This is a 45.13 percent increase over sales of $27.208 million the same period last year.

Earnings Beats

INBK

First Internet Q4 2024 Adj. EPS $0.41 Down From $0.48 YoY, Sales $39.487M Beat $24.332M Estimate

Origin Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OBK#NYSE">OBK</a>) reported quarterly earnings of $0.46 per share which missed the analyst consensus estimate of $0.51 by 9.8 percent. The company reported quarterly sales of $78.02 million which missed the analyst consensus estimate of $87.75 million by 11.09 percent. This is a 3.90 percent decrease over sales of $81.19 million the same period last year.

Earnings Misses

Origin Bancorp Q4 2024 Sales $78.02M Miss $87.75M Estimate

Amerant Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMTB#NYSE">AMTB</a>) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $0.33 by 51.52 percent. This is a 8.7 percent increase over earnings of $0.46 per share from the same period last year. The company reported quarterly sales of $105.45 million which beat the analyst consensus estimate of $100.57 million by 4.86 percent. This is a 10.31 percent increase over sales of $95.60 million the same period last year.

AMTB

Amerant Bancorp Q4 Adj $0.50 Beats $0.36 Estimate, Sales $105.45M Beat $100.56M Estimate

Electronic Arts Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) shares are moving lower in after-hours Wednesday after the company reported preliminary financial results <a href="https://www.benzinga.com/pressreleases/25/01/b43143872/electronic-arts-pre-announces-preliminary-q3-fy25-results">for the third quarter</a>.
What Happened: EA said it previously anticipated mid-single-digit growth in live services net bookings, but now projects a mid-single-digit decline largely due to a slowdown in Global Football.
The Global Football franchise experienced a slowdown in the quarter as early momentum faded, the company said. Separately, Dragon Age only engaged approximately 1.5 million players during the quarter, about 50% lower than the company&#8217;s expectations. 
Due to the unexpected slowdown, EA reported preliminary results for the third quarter and adjusted its full-year outlook. EA now expects third-quarter revenue of $1.883 billion versus estimates of $2.507 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company anticipates third-quarter earnings of $1.11 per share, in line with analyst estimates. 
EA now expects net bookings of approximately&nbsp;$2.215 billion&nbsp;in the third quarter. The company provided a net bookings range of&nbsp;$7 billion&nbsp;to&nbsp;$7.15 billion&nbsp;for fiscal year 2025.
&#8220;During&nbsp;Q3, we continued to deliver high-quality games and experiences across our portfolio; however, Dragon Age and EA SPORTS FC 25 underperformed our net bookings expectations,&#8221; said Andrew Wilson, CEO of EA. 
&#8220;This month, our teams delivered a comprehensive gameplay refresh in addition to our annual Team of the Year update in FC 25; positive player feedback and early results are encouraging. We remain confident in our long-term strategy and expect a return to growth in FY26, as we execute against our pipeline.&#8221;
EA will report its full financial results for the third quarter after the market close on Feb. 4.
EA Price Action: <a href="http://benzinga.com/quote/ea">EA shares</a> were down 8.56% at $130.16 in after-hours trading at the time of publication, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/25/01/43136402/netflix-stock-firing-on-all-cylinders-10-analysts-react-to-q4-beat-guidance-price-increases">Netflix Stock &#8216;Firing On All Cylinders&#8217;: 10 Analysts React To Q4 Beat, Guidance, Price Increases</a></li>
</ul>
Photo: Shutterstock.

Gaming

Guidance

Electronic Arts Stock Is Sliding After The Close: What's Going On?

STLD

Steel Dynamics Says Market Dynamics Are In Place To Support Increased Demand Across Operating Platforms In 2025

Steel Dynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>) reported quarterly earnings of $2.05 per share which beat the analyst consensus estimate of $1.42 by 44.37 percent. This is a 21.46 percent decrease over earnings of $2.61 per share from the same period last year. The company reported quarterly sales of $3.87 billion which missed the analyst consensus estimate of $3.95 billion by 2.07 percent. This is a 8.53 percent decrease over sales of $4.23 billion the same period last year.

Steel Dynamics Q4 2024 GAAP EPS $2.05 Beats $1.42 Estimate, Sales $3.87B Miss $3.95B Estimate

Telsey Advisory Group analyst Joseph Feldman maintains Grocery Outlet Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GO#NASDAQ">GO</a>) with a Market Perform and maintains $18 price target.

Price Target

Analyst Ratings

Telsey Advisory Group Maintains Market Perform on Grocery Outlet Holding, Maintains $18 Price Target

MasTec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) has been analyzed by 10 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $169.4, along with a high estimate of $195.00 and a low estimate of $150.00. Witnessing a positive shift, the current average has risen by 19.3% from the previous average price target of $142.00.
<img src="https://www.benzinga.com/files/images/story/2025/1737583329_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of MasTec among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Brophy</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$185.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Sangita Jain</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$168.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Joseph Osha</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$195.00</td>
<td>-</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$189.00</td>
<td>$173.00</td>
</tr>
<tr>
<td>Brian Brophy</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$155.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Alex Rygiel</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$166.00</td>
<td>$151.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$173.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Christian Schwab</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Marc Bianchi</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$160.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Andrew Wittmann</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$153.00</td>
<td>$120.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to MasTec. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of MasTec compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of MasTec's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into MasTec's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MTZ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on MasTec analyst ratings.</a>
<h2>About MasTec</h2>
MasTec is a leading infrastructure construction company operating mainly in North America across a range of industries. The company's primary activities include the engineering, building, installation, maintenance, and upgrade of communications, oil and gas, utility, renewable energy, and other infrastructure. MasTec reports its results under five reportable segments: communications; clean energy and infrastructure; oil and gas; power delivery; and other.
<h3>MasTec's Financial Performance</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Challenges: MasTec's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -0.14%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: MasTec's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 2.93%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): MasTec's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 3.45%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 1.09%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: MasTec's debt-to-equity ratio stands notably higher than the industry average, reaching 0.97. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

10 Analysts Assess MasTec: What You Need To Know

Ratings for Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) were provided by 32 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">11</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">3</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $358.81, with a high estimate of $550.00 and a low estimate of $24.86. Witnessing a positive shift, the current average has risen by 27.0% from the previous average price target of $282.53.
<img src="https://www.benzinga.com/files/images/story/2025/1737583316_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Tesla. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$550.00</td>
<td>$515.00</td>
</tr>
<tr>
<td>Alexander Potter</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$500.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Dan Levy</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$325.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Adam Jonas</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$430.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>John Murphy</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$490.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$492.00</td>
<td>$411.00</td>
</tr>
<tr>
<td>Chris McNally</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$275.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$404.00</td>
<td>$298.00</td>
</tr>
<tr>
<td>William Stein</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$351.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Gordon Johnson</td>
<td>GLJ Research</td>
<td>Maintains</td>
<td>Sell</td>
<td>$24.86</td>
<td>$24.86</td>
</tr>
<tr>
<td>William Stein</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Hold</td>
<td>$360.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Ben Kallo</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$480.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$515.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Mark Delaney</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$345.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Neutral</td>
<td>$365.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Adam Jonas</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$400.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Edison Yu</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$370.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Ronald Jewsikow</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Sell</td>
<td>$175.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>John Murphy</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$400.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Craig Irwin</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$380.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$411.00</td>
<td>$287.00</td>
</tr>
<tr>
<td>Joseph Spak</td>
<td>UBS</td>
<td>Raises</td>
<td>Sell</td>
<td>$226.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Tom Narayan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$313.00</td>
<td>$249.00</td>
</tr>
<tr>
<td>Philippe Houchois</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$300.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$400.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>John Murphy</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$350.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Alexander Potter</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$315.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Dan Levy</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$235.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$298.00</td>
<td>$278.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$287.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Alexander Potter</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$315.00</td>
<td>$310.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Tesla. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Tesla compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Tesla's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Tesla's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TSLA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Tesla analyst ratings.</a>
<h2>About Tesla</h2>
Tesla is a vertically integrated battery electric vehicle automaker and developer of autonomous driving software. The company has multiple vehicles in its fleet, which include luxury and midsize sedans, crossover SUVs, a light truck, and a semi truck. Tesla also plans to begin selling more affordable vehicles, a sports car, and a robotaxi. Global deliveries in 2024 were a little below 1.8 million vehicles. The company sells batteries for stationary storage for residential and commercial properties including utilities and solar panels and solar roofs for energy generation. Tesla also owns a fast-charging network.
<h3>Tesla's Economic Impact: An Analysis</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Positive Revenue Trend: Examining Tesla's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 7.85% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 8.61%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Tesla's ROE stands out, surpassing industry averages. With an impressive ROE of 3.18%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Tesla's ROA stands out, surpassing industry averages. With an impressive ROA of 1.86%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.18, Tesla adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Tesla Stock: A Deep Dive Into Analyst Perspectives (32 Ratings)

During the last three months, 17 analysts shared their evaluations of Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Oracle and provided 12-month price targets. The average target is $195.47, accompanied by a high estimate of $220.00 and a low estimate of $150.00. Marking an increase of 9.74%, the current average surpasses the previous average price target of $178.12. 
<img src="https://www.benzinga.com/files/images/story/2025/1737583308_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Oracle. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$205.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Thomas Blakey</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$214.00</td>
<td>-</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$194.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$210.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$175.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$205.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$205.00</td>
<td>$173.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$150.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$165.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Siti Panigrahi</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$210.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Kirk Materne</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$175.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$165.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>John Difucci</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$220.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$220.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Jason Ader</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Oracle. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Oracle compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Oracle's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Oracle's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ORCL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Oracle analyst ratings.</a>
<h2>All You Need to Know About Oracle</h2>
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has more than 400,000 customers in 175 countries.
<h3>Understanding the Numbers: Oracle's Finances</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Positive Revenue Trend: Examining Oracle's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 8.64% as of 30 November, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: Oracle's net margin excels beyond industry benchmarks, reaching 22.41%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 25.66%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.15%, the company showcases effective utilization of assets.
Debt Management: Oracle's debt-to-equity ratio surpasses industry norms, standing at 6.45. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ORCL

Deep Dive Into Oracle Stock: Analyst Perspectives (17 Ratings)

Across the recent three months, 9 analysts have shared their insights on Old National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONB#NASDAQ">ONB</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $27.0, a high estimate of $29.00, and a low estimate of $25.00. Observing a 8.52% increase, the current average has risen from the previous average price target of $24.88. 
<img src="https://www.benzinga.com/files/images/story/2025/1737583299_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Old National among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Karl Shepard</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$26.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>David Long</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$29.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Terry McEvoy</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$27.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>David Long</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Strong Buy</td>
<td>$28.00</td>
<td>-</td>
</tr>
<tr>
<td>Jon Arfstrom</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$25.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Christopher Mcgratty</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$28.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$26.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Scott Siefers</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$27.00</td>
<td>$23.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Old National. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Old National compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Old National's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Old National's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ONB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Old National analyst ratings.</a>
<h2>All You Need to Know About Old National</h2>
Old National Bancorp with almost $10 billion in assets following its latest acquisition, Old National Bancorp is a financial services bank holding company headquartered in Indiana. Based in Evansville, Ind., Old National owns multiple financial services operations in Indiana, Illinois, and Kentucky. The company provides a group of similar community banking services, including such products and services as commercial, real estate, and consumer loans; deposits; and brokerage, trust, and investment advisory services.
<h3>Unraveling the Financial Story of Old National</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Old National's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 6.54%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Old National's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 28.77%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Old National's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.33%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Old National's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.26%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.83, caution is advised due to increased financial risk.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Old National In The Eyes Of 9 Experts

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Adient (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADNT#NYSE">ADNT</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Adient, revealing an average target of $21.0, a high estimate of $24.00, and a low estimate of $19.00. Experiencing a 17.65% decline, the current average is now lower than the previous average price target of $25.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1737583289_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Adient is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dan Levy</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$21.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Colin Langan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>John Murphy</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Adam Jonas</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$19.00</td>
<td>$21.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Adient. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Adient compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Adient's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Adient's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ADNT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Adient analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Adient: A Closer Look</h2>
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is the leading seating supplier to the industry with about one third of the global market. Its share in China is now nearly 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.8 billion in fiscal 2024 and consolidated China revenue was $1.4 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2024 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.7 billion.
<h3>Unraveling the Financial Story of Adient</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Negative Revenue Trend: Examining Adient's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -4.48% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Adient's net margin excels beyond industry benchmarks, reaching 2.22%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Adient's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.89% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Adient's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.86%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a high debt-to-equity ratio of 1.13, Adient faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADNT

4 Analysts Have This To Say About Adient

Across the recent three months, 11 analysts have shared their insights on 3M (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for 3M, revealing an average target of $153.73, a high estimate of $184.00, and a low estimate of $96.00. Observing a 6.96% increase, the current average has risen from the previous average price target of $143.73. 
<img src="https://www.benzinga.com/files/images/story/2025/1737583277_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of 3M among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Underperform</td>
<td>$96.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Andrew Obin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$175.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$152.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$161.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Joe O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$170.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$162.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$161.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Matthew Swanson</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$96.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Damian Karas</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$184.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$160.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to 3M. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of 3M compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of 3M's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of 3M's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MMM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on 3M analyst ratings.</a>
<h2>Discovering 3M: A Closer Look</h2>
3M, a multinational conglomerate founded in 1902, sells tens of thousands of products ranging from sponges to respirators. The firm is well known for its extensive research and development capabilities, and it is a pioneer in inventing new use cases for its proprietary technologies. 3M is organized across three business segments: safety and industrial (representing around 44% of revenue), transportation and electronics (36%), and consumer (20%). The firm recently spun off its healthcare business, now known as Solventum. Nearly half of 3M's revenue comes from outside the Americas.
<h3>3M's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Positive Revenue Trend: Examining 3M's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 0.38% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: 3M's net margin excels beyond industry benchmarks, reaching 21.8%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): 3M's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 32.06% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 3.26%, the company showcases effective utilization of assets.
Debt Management: 3M's debt-to-equity ratio is below the industry average at 2.97, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into 3M Stock: Analyst Perspectives (11 Ratings)

TD Synnex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) has outperformed the market over the past 5 years by 1.92% on an annualized basis producing an average annual return of 15.08%. Currently, TD Synnex has a market capitalization of $11.92 billion. 
Buying $1000 In SNX: If an investor had bought $1000 of SNX stock 5 years ago, it would be worth $2,034.38 today based on a price of $141.50 for SNX at the time of writing.
<h3>TD Synnex's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737583212_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning TD Synnex Stock In The Last 5 Years

Hexcel shares are trading lower after the company issued FY25 adjusted EPS guidance below estimates.

Verve Therapeutics: Cutting Edge Science But Highly Risky Stock

Verve Therapeutics: Cutting-Edge Science But Highly Risky Stock

After NewAmsterdam Pharma (NAMS) announced "positive" topline data from the company's Phase 3 BROADWAY trial evaluating obicetrapib in adult patien...

Verve Therapeutics has positive read from NewAmsterdam data, says Stifel

Stifel Nicolaus analyst Dae Gon Ha maintained a Buy rating on Verve Therapeutics (VERV – Research Report) today. The company's shares opened today ...

Stifel Nicolaus Sticks to Their Buy Rating for Verve Therapeutics (VERV)

Small-cap healthcare stocks offer a unique opportunity for investors looking to capitalize on innovation and high growth. Thus, investors might consider keeping an eye on three small-cap healthcare stocks, Verve Therapeutics (VERV), Immatics N.V. (IMTX), and Esperion Therapeutics (ESPR), that offer big upside potential. Read on… Small-cap healthcare companies are companies with a market capitalization of <a href="https://www.investopedia.com/terms/s/small-cap.asp">up to $2 billion</a>, which often go unnoticed, but they hold immense potential for investors seeking high-growth opportunities. These companies are typically at the forefront of innovation, focusing on niche markets or groundbreaking therapies.
Below, I have highlighted three small-cap healthcare stocks: Verve Therapeutics, Inc. (<a href="https://stocknews.com/stock/VERV/">VERV</a>), Immatics N.V. (<a href="https://stocknews.com/stock/IMTX/">IMTX</a>), and Esperion Therapeutics, Inc. (<a href="https://stocknews.com/stock/ESPR/">ESPR</a>), offering significant upside potential.
The key driver of small-cap healthcare companies is their focus on specialized treatments. Many of these companies are involved in developing therapies for rare diseases or unmet medical needs, which often come with lucrative market exclusivity periods. The successful commercialization of even a single product can lead to exponential growth for these firms.
According to Deloitte's outlook, <a href="https://www2.deloitte.com/us/en/insights/industry/health-care/life-sciences-and-health-care-industry-outlooks/2025-us-health-care-executive-outlook.html">2025 might be a turnaround period for the healthcare sector</a> driven by innovation, resilience, and strategic growth. As global healthcare spending continues to rise, fueled by aging populations and increased focus on innovation, small-cap companies will likely see sustained demand for their specialized offerings.
The global healthcare market is projected to reach $44.760 trillion by 2032, <a href="https://www.globenewswire.com/news-release/2024/08/01/2923001/0/en/Healthcare-Market-Size-Worth-US-44-760-73-Billion-By-2032-Continuous-Advancements-in-Biotechnology-Pharmaceuticals-Propels-Growth-Research-by-SNS-Insider.html">exhibiting a CAGR of 9.1%</a>. This growth signifies increased investment and innovation, driving further advancements and improvements in patient care.
With that in mind, let's delve into the fundamentals of the three <a href="https://stocknews.com/category/biotech/">Biotech</a> stock picks, starting with the third choice.
Stock #3: Verve Therapeutics, Inc. (<a href="https://stocknews.com/stock/VERV/">VERV</a>)
With a market cap of $508.83 million, VERV is a clinical-stage genetic medicines company that engages in developing gene-editing medicines for patients to treat cardiovascular diseases. The company's product portfolio consists of VERVE-101, VERVE-102, and ANGPTL3 programs.
VERV, for the third quarter (ended September 30, 2024), reported collaboration <a href="https://www.investopedia.com/terms/r/revenue.asp">revenue</a> of $6.87 million, indicating a 120.2% growth from the prior-year quarter. Its cash and cash equivalents and total assets came in at $158.71 million and $663.91 million as of September 30, 2024.
For the fiscal year (ended December 2024), Street expects VERV's revenue to grow by 99.4% year-over-year to $23.44 million.
VERV's total assets have grown at a CAGR of 17.4% over the past three years. Likewise, the company's tangible book value has increased at a CAGR of 9.7% over the past three years.
VERV shares have surged 32.9% over the past three months and 6% over the past six months to close the last trading session at $6.01.
The 12-month median price target of $25.67 indicates <a href="https://www.tipranks.com/stocks/verv/forecast">a 327.1% upside potential</a> from the last closing price. The price targets range from a low of $15 to a high of $35.
VERV's stance is apparent in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
Among the 339 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, it is ranked #123. <a href="https://stocknews.com/stock/VERV/">Click here</a> to see the VERV ratings (Growth, Value, Momentum, Stability, Sentiment, and Quality).
Stock #2: Immatics N.V. (<a href="https://stocknews.com/stock/IMTX/">IMTX</a>)
Based in Tübingen, Germany, IMTX, a clinical-stage biopharmaceutical company, is focused on researching and developing potential T-cell redirecting immunotherapies for cancer treatment. It is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities. It has a market cap of $847.20 million.
In the fiscal third quarter that ended on September 30, 2024, IMTX's revenue from collaboration agreements increased 753.2% year-over-year to €50.56 million ($52.54 million). As of September 30, 2024, IMTX's cash reached €189.19 million ($196.62 million), with total assets amounting to €577.23 million ($599.88 million) as of September 30, 2024.
Analysts expect IMTX's revenue for the fiscal year (ending December 2024) to grow 106.9% year-over-year to $121.27 million. 
Over the past three years, IMTX's revenue and total assets grew at CAGRs of 59.5% and 42.6%, respectively.
The stock has declined marginally intraday to close the last trading session at $6.97.
Based on Wall Street analysts offering 12-month price targets for IMTX in the last three months, <a href="https://www.tipranks.com/stocks/imtx/forecast">the average target price is $16.58</a>, indicating a 137.9% change from the last price.
IMTX's POWR Ratings reflect this outlook. It has a B grade for Value and is ranked #58 out of 339 stocks in the same industry. To see the other ratings of IMTX for Growth, Value, Momentum, Stability, Sentiment, and Quality, <a href="https://stocknews.com/stock/IMTX/">click here</a>.
Stock #1: Esperion Therapeutics, Inc. (<a href="https://stocknews.com/stock/ESPR/">ESPR</a>)
ESPR is a pharmaceutical company that has a market cap of $427.57 million, and it develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL and NEXLIZET tablets for treating primary hyperlipidemia in adults who require additional LDL-C lowering.
On December 12, ESPR announced that it has entered into a licensing agreement with Neopharm Israel for the exclusive rights to commercialize NEXLETOL&#xAE; (bempedoic acid) and NEXLIZET&#xAE; (bempedoic acid and ezetimibe) in Israel.
In this agreement, ESPR will receive an upfront payment, near-term milestones, and tiered royalties. This agreement should also expand ESPR's global reach for cardiovascular and cardiometabolic diseases.
On September 3, ESPR announced additional commercial and medicare coverage for NEXLETOL&#xAE; (bempedoic acid) and NEXLIZET&#xAE; (bempedoic acid and ezetimibe). This addition provides access to more than 65% of medicare lives and more than 92% of commercially insured lives, allowing the healthcare providers to prescribe it to primary and secondary prevention patients easily.
For the nine-month period that ended on September 30, 2024, ESPR's total revenues increased 213% year-over-year to $263.20 million. Its income from operation came in at $58.82 million compared to a year-ago net loss of $113.19 million. The company's cash and cash equivalents and total assets came in at $144.72 million and $314.11 million as of September 30, 2024.
Street expects ESPR's revenue for the fiscal fourth quarter (ended December 2024) to increase 92.7% year-over-year to $62.14 million. In addition, it surpassed the revenue estimates in three of the trailing four quarters, which is promising.
Moreover, ESPR's revenue has grown at CAGRs of 59.6% and 14.9% over the past three and five years, respectively. In addition, its total assets increased at 11.7% CAGR over the past three years. 
Over the past three months, the stock has surged 4.8%, closing the last trading session at $2.17.
Based on Wall Street analysts offering 12-month price targets for ESPR in the last three months, <a href="https://www.tipranks.com/stocks/espr/forecast">the average target price is $6.86</a>, indicating a 216.1% change from the last price, with a high forecast of $16 and a low forecast of $2.05.
ESPR's fundamentals are reflected in its POWR Ratings. The stock has a B grade for Growth, Value, and Quality. It is ranked #42 in the Biotech industry.
Beyond what is stated above, we've also rated ESPR for Momentum, Stability, and Sentiment. Get all ESPR's ratings <a href="https://stocknews.com/stock/ESPR/">here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
IMTX shares were trading at $6.97 per share on Thursday afternoon, down $0.07 (-0.99%). Year-to-date, IMTX has declined -1.97%, versus a 0.58% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: ShreyaRathi</h2> <img src='https:/wp-content/uploads/2024/10/0.jpeg' style="float:left; padding:5px;width:125px;"><a href="https://stocknews.com/authors/?author=shreya-rathi">More...</a>The post <a href=https://stocknews.com/news/imtx-verv-espr-3-small-cap-healthcare-stocks-with-big-upside-potential/>3 Small-Cap Healthcare Stocks With Big Upside Potential</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Small-Cap Healthcare Stocks With Big Upside Potential

Gene editing stocks drop as Intellia announces layoffs

Pipeline Updates and 2025 Anticipated Milestones: PCSK9 Program: Initial Data for the Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102 Expected...

Verve Therapeutics announces anticipated 2025 milestones

With Verve's existing cash, cash equivalents and marketable securities, including the milestone payment to be received from Lilly under the Lp(a) p...

Verve Therapeutics sees cash runway into mid-2027

CRSP

EDIT

ESPR

IMTX

LENZ

NAMS

PRME

SGMO

Legal

Press Releases

VERV DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV

Verve Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before October 28, 2024 to Discuss Your Rights - VERV

Small Cap

Verve Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VERV

VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results

Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

General

Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones

Akebia Therapeutics

Altimmune

AnaptysBio

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

Cargo Therapeutics

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Emergent BioSolutions

Erasca

GRAIL

Humacyte

Immunome

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

Keros Therapeutics

Kura Oncology

MeiraGTx Hldgs

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Stoke Therapeutics

Savara

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Entrada Therapeutics, Inc. - Common Stock

Entrada Therapeutics

Upstream Bio

Canaccord Genuity

RBC Capital

HC Wainwright & Co.

Stifel

Cantor Fitzgerald

수요일에 캐시 우드가 이끄는 아크 인베스트(Ark Invest)는 이 회사의 인상적인 2분기 납품 실적에 힘입은 최근 상승세에도 불구하고 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)의 상당 수의 주식을 매각하여 주목할만한 움직임을 보였다.
테슬라 주식
아크 인베스트는 ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)를 통해 테슬라 지분을 줄여 13,213주를 매각했다. 이번 거래는 테슬라의 주가가 최근 화요일에 10.20% 급등해 4월 말 이후 최고의 장중 거래를 기록했다는 점을 감안하면 놀라운 일이었다. 특히 화요일에 아크 인베스트는 <a href="https://www.benzinga.com/markets/equities/24/07/39611275/cathie-woods-ark-invest-sells-tesla-shares-worth-14-5m-amid-rally-driven-by-q2-delivery-numbers-">1,450만 달러</a> 상당의 테슬라 주식을 매각했다.
이러한 상승은 주로 일론 머스크가 이끄는 이 회사의 <a href="https://www.benzinga.com/markets/equities/24/07/39595720/tesla-deliveries-fall-for-second-straight-quarter-but-stock-takes-off-as-q2-numbers-exceed-expec">2분기 실적</a>에 의해 주도되었다. 테슬라는 예상 차량 439,000대를 크게 초과하는 443,956대를 인도했다고 보고했다. 이러한 놀라운 상승세는 랠리를 촉진하여 주가를 2024년 최고치로 끌어올렸다. 판매의 대부분은 저렴한 모델 3 및 Y에서 이루어졌으며, 더 비싼 모델 X, S 및 신형 사이버트럭에서는 21,551대만 판매되었다.
최종 종가 246.39달러를 기준으로 수요일에 판매된 주식의 가치는 약 325만 달러에 달한다. 이날 테슬라 주가는 6.5% 급등했다.
기타 중요한 거래:
<ul>
<li>아크 인베스트의 ARKF 펀드는 텔레닥(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>)의 주식을 팔았다.</li>
<li>ARKG 펀드는 인텔리아 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>)의 주식을 2,551주 매수하고, 버브 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>)의 주를 팔았다.</li>
<li>ARKK 펀드는 아처 에비에이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NASDAQ">ACHR</a>)의 주를 사고, 깅코 바이오웍스 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NYSE">DNA</a>)의 주를 팔았다.</li>
<li>ARKQ 펀드는 에어로바이런먼트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>)의 주를 팔았다. ARKX 펀드는 블레이드 에어 모빌리티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDE#NASDAQ">BLDE</a>)의 주를 샀다.</li>
</ul>
이미지는 셧터스톡을 통해 제공됨
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>이 편집했다

월요일에는 캐시 우드가 주도하는 아크 인베스트(Ark Invest)가 몇 가지 중요한 거래를 했으며, 그 가운데 코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)의 거래가 주목을 받았다. 이는 특히 암호화폐의 경우 격동적인 시장 시나리오 속에서 발생했다.
코인 거래
이날 아크 인베스트의 가장 눈에 띄는 거래는 대표적인 암호화폐 거래소 플랫폼인 코인베이스와의 거래였다. 이번 거래는 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) ​​가격이 62,000달러 아래로 떨어지는 등 <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39459091/coinbase-shares-tumble-with-bitcoin-whats-going-on-with-the-stock" target="_blank" rel="noopener" data-google-interstitial="false">암호화폐 시장이 상당한 변동성</a>을 겪고 있는 시기에 이루어졌다. 이러한 비트코인 ​​가격 하락은 코인베이스 주가에 직접적인 영향을 미쳤으며 월요일에도 하락세를 보였다.
코인베이스 주가는 월요일 정규 세션이 끝날 때 212.31달러를 기록했다. 이 회사는 ARK 차세대 인터넷 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)를 통해 3,341개의 코인베이스 주식을 매도했다. 이 거래 금액은 709,327달러이다.
기타 중요한 거래:
<ul>
<li>텔레닥 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>): ARKG ETF에서 54,256주, ARKK ETF에서 61,606주를 매도했다.</li>
<li>앱사이이(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>): ARKG ETF를 통해 43,936주를 매수했다.</li>
<li>버브 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>): ARKG ETF에서 10,570주, ARKK ETF에서 50,971주를 매도했다.</li>
<li>로쿠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>): ARKK ETF를 통해 32,989주를 매수했다.</li>
</ul>
다음 읽기: <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39448829/bitcoin-ethereum-dogecoin-fall-on-investor-worries-analyst-warns-of-king-cryptos-dip-below?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">투자자 우려로 비트코인, 이더리움, 도지코인 가격 하락</a>
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>에서 제공한 내용을 바탕으로 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>이 수정했습니다.

캐시 우드가 이끄는 아크 인베스트(Ark Invest)는 수요일에 로빈후드 마켓(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) 및 줌 비디오 커뮤니케이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>)괴 관련하여 상당한 거래를 했다.
로빈후드 주식의 거래
아크 인베스트는 Ark Fintech Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>)와 ARK Next Generation Internet ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)를 통해 약 153만 달러 상당의 로빈후드 주식 64,706주를 매각했다. 이러한 움직임은 이 회사가 최근 시장 변동으로 인해 로빈후드의 <a href="https://www.benzinga.com/markets/equities/24/06/39263031/cathie-wood-lead-ark-invest-dumps-7-6m-worth-of-robinhood-shares-amid-gamestop-buzz-bitcoin-chop">보유 지분</a>을 줄인 후에 나온 것이다. 이 회사의 주가는 현재 5월 영업 데이터 발표 이후 상승하고 있다.
특히 로빈후드 거래는 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)과 이더리움(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)의 가격이 약간의 상승세를 보였지만 연방준비은행(연준)의 금리 인하에 대한 매파적인 지침으로 인해 <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39303902/bitcoin-ethereum-dogecoin-fail-to-sustain-uptrend-after-feds-hawkish-guidance-analyst-fore" target="_blank" rel="noopener" data-google-interstitial="false">이 랠리는 지속되지 않았다</a>.
줌 주식 거래
아크 인베스트는 ARKW를 통해 54,165주, 약 330만달러 상당의 줌 주식을 매도했다. 이 결정은 회사가 지난달 <a href="https://www.benzinga.com/news/earnings/24/05/38926994/zoom-q1-earnings-revenue-beat-eps-beat-cash-flow-surges-continued-ai-integration-and-more">매출과 이익 예상치를 뛰어넘는 강력한 1분기 실적을 발표한 </a>이후의 결정이다.
다른 중요한 거래들:
<ul>
<li>아크 인베스트는 마크포지드 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MKFG#NYSE">MKFG</a>)의 주식 21,260주를 ARK Autonomous Technology &amp; Robotics ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>)를 통해 매수했다. 아크 인베스트는 ARK Space Exploration &amp; Innovation ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>)를 통해 마크포지드 8,776주를 구매했다.</li>
<li>아크 인베스트는 페이저듀티(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>)의 주식 15,383주를 ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)를 통해 구매했다. 아크 인베스트는 ARK Genomic Revolution ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)를 통해 아크투러스 테라퓨틱스 홀딩스(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/arct" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for ARCT">ARCT</a>)주식 39,589주를 매수했다.</li>
<li>아크 인베스트는 ARKW ETF를 통해 텔레닥 헬스 주식 229,654주를 매도했다. 아크 인베스트는 ARKK ETF를 통해 버브 테라퓨틱스 주식 125,257주를 매도했다. 이 회사는 ARKG ETF를 통해 버브 테라퓨틱스 주식 24,866주를 매도했다.</li>
</ul>
본 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 통해 제작되었으며, <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>이 수정했습니다.

월요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 로빈후드 마켓(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>)의 지분을 줄이는 중요한 조치를 취했다. 이 결정은 시장 변동 기간 중에 이루어졌으며 이 투자 회사가 자체 포트폴리오를 조정하는 최근 추세를 따랐다.
로빈후드(HOOD) 매매:
로빈후드에서 포지션을 축소하기로 한 아크 인베스트의 결정은 세 가지 ETF를 통해 실행되었다. ARK Fintech Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>)는 31,827주를 매각했고, ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)와 ARK Next Generation Internet ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)는 각각 215,675주와 76,299주를 매각했다. 월요일 로빈후드의 종가 23.42달러를 기준으로 판매된 주식의 총 가치는 약 760만 달러이다.
로빈후드 주식의 변동성은 <a href="https://www.benzinga.com/news/24/06/39234943/whats-going-on-with-robinhood-stock" target="_blank" rel="noopener">밈 주식 열기가 부활</a>하는 가운데 발생했다. 최근 로빈후드의 CEO 블래디미어 테네브는 게임스탑에 투자한 것으로 유명한 로어링 키티(Roaring Kitty)이라고도 알려진 키스 길(Keith Gill)의 예정된 라이브 스트리밍으로 인한 트래픽 유입을 회사가 처리할 준비가 되었다고 발표했다. 이 회사는 또한 최근 <a href="https://www.benzinga.com/news/24/05/39047461/robinhood-markets-stock-jumps-on-1b-buyback-whats-going-on">10억 달러 규모의 자사주 매입</a>을 발표했는데, 이는 주가 상승 추세에 기여했다.
특히 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)과 이더리움(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) 등 주요 코인들이 적자로 거래되면서 <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39262872/bitcoin-ethereum-dogecoin-remain-choppy-analyst-forecasts-2x-10x-increase-for-king-crypto-" target="_blank" rel="noopener">고르지 못한 암호화폐 시장</a>을 배경으로 거래가 성사됐다.
다른 중요한 거래:
<ul>
<li>이그젝트 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>): ARKG 및 ARKK를 통해 주식 매도.</li>
<li>아크투러스 테라퓨틱스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>): ARKG를 통해 주식 매입.</li>
<li>텔라닥 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>): ARKG를 통해 주식 매도.</li>
<li>인텔리아 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>): ARKG 및 ARKK를 통해 주식 매입.</li>
<li>버브 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>): ARKG 및 ARKK를 통해 주식 매도. 베라사이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>): ARKG 및 ARKK를 통해 5,804주 매입.</li>
</ul>
다음 읽어보기: <a href="https://www.benzinga.com/markets/equities/24/06/39246807/investor-naval-ravikant-threatens-to-sell-all-tesla-holdings-if-ceo-musks-pay-plan-is-rejected-b?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">CEO 일자리 대안에 대한 투자자의 협상</a>
이 이야기는 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>의 편집을 거쳐 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>에 의해 제작되었습니다.

EXAS

VCYT

아크 인베스트가 게임스톱 관련 뉴스와 비트코인 변동성 속에서 로빈후드 주식 $7.6백만 매각

목요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 아마존닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)과 레딧(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>)에서 상당한 거래를 성사시켰으며 두 회사 모두 눈에 띄는 움직임을 보였다.
아마존닷컴 거래:
아크 인베스트의 ARK 차세대 인터넷 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)는 아마존 주식 53,368주를 매입했다. 이러한 움직임은 Amazon이 최근 760억 달러 규모의 11년 계약의 일환으로 NBA 미디어 권리를 <a href="https://www.benzinga.com/general/sports/24/06/39215473/amazon-makes-prime-bet-on-sports-with-nba-deal-streaming-platform-will-have-content-from-4-major-l">인수</a>한 이후에 나온 것이다. 이러한 전략적 움직임은 아마존 프라임 비디오(Amazon Prime Video) 스트리밍 플랫폼의 가입자 수를 늘릴 것으로 예상된다. 목요일 아마존의 종가 185달러를 기준으로 한 이번 거래 가치는 약 990만 달러이다.
레딧 거래:
별도의 거래에서, 아크 인베스트의 Ark 핀테크 혁신 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>)는 레딧 주식 1,312주를 매입했다. 이번 매입은 레딧이 최근 고객 경험 관리 플랫폼 기업 스프링클(Sprinklr)과의 <a href="https://www.benzinga.com/news/24/06/39208968/whats-going-on-with-reddit-stock-today">확대된 파트너십 발표한</a> 것과 일치한다. 이 파트너십을 통해 스프링클 고객들은 레딧의 전체 광고 제품군에 액세스하고 레딧을 기업 광고 전략에 통합할 수 있다. 레딧의 목요일 종가 63.46달러를 기준으로 한 이 거래의 가치는 약 83,200달러이다.
다른 중요한 거래:
<ul>
<li>아크 인베스의 ARKG 펀드는 인텔리아 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) 주식 25,736주를 매입하고, 이그젝트 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>)의 12,602주를 팔았다.</li>
<li>ARKK 펀드는 페이저듀티(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>)의 106,192주를 매입하고, 버브 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>)의 126,699주를 팔았다. ARKW 펀드는 서비스나우(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>)의 14,121주를 매도했다.</li>
</ul>
다른 중요한 거래를 읽어보세요: <a href="https://www.benzinga.com/markets/equities/24/06/39192292/amc-stock-rises-as-annual-shareholder-meeting-results-roll-in-whats-going-on?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">AMC주가 상승, 연례 주주총회 결과 발표: 무슨 일이?</a>
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>에 의해 작성되었으며 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>에 의해 편집되었습니다.

AMZN

RDDT

캐시 우드가 이끄는 아크 인베스트는 아마존 주식을 990만 달러 상당 매수, 레딧도 매입

목요일, 캐시 우드(Cathie Wood)가 이끄는 아크 인베스트(Ark Invest)가 같은 날 주식의 긍정적인 시장 실적에도 불구하고 코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) 주식을 매각하여 상당한 움직임을 보였다.
COIN의 트레이드
코인베이스 주식을 매각하기로 한 아크 인베스의 결정은 거래 당일 주식의 상승 궤적을 고려할 때 많은 사람들에게 놀라운 일이었다. 특히 비트코인(CRYPTO: <a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/btc-usd" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for BTC/USD">BTC</a>) ​​및 이더리움(CRYPTO: <a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/eth-usd" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for ETH/USD">ETH</a>)과 같은 주요 암호화폐는 이 기사 작성  시점에 혼합 거래되었다. 비트코인은 2.7% 높은 67,632.08달러로 나타났고, 이더리움은 0.3% 낮은 3,268.90달러에 거래되었다.
<a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38091237/coinbase-stock-is-rising-thursday-whats-going-on">벤징가</a> 보고서에 따르면 코인베이스 주식은 목요일 상승했다. 이번 거래에 참여한 ETF는 각각 22,690주와 2,972주의 주식을 판매했던 아크 핀테크 이노베이션 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)와 아크 넥스트 제너레이션 인터넷 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)였다. 이 거래의 가치는 최근 249.61달러의 종가에서 약 640만 달러에 해당한다.
재미있는 점은 뉴욕 소재의 금융기관인 오펜하이머 (Oppenheimer)가 코인베이스의 목표 주가를 200달러에서 276달러로 <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38092813/oppenheimer-raises-coinbase-share-price-target-to-276">상향 조정한 날</a>이기도 했다. 이 날의 새로운 목표 가격은 코인베이스의 종가 251.58달러보다 약 10% 높다.
기타 주요 거래:
<ul>
<li>ARKF는 소파이 테크놀로지스(SoFi Technologies Inc) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>)와 로블록스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>)의 주식을 구매.</li>
<li>ARKF는 트윌리오 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>)의 주식을 판매, ARKG는 10x 지노믹스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>)와 벌브 테라퓨틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>)의 주식을 구매.</li>
<li>ARKF는 로쿠 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>)의 주식을 구매, 트윌리오 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>)의 주식을 판매.</li>
</ul>
다음 읽기: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38063416/chuck-meme-coin-that-aims-to-make-ethereum-great-again-skyrockets-25-800-hours-after-launc?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">이더리움을 다시 위대하게 만드는 CHUCK Meme Coin, 출시 후 25,800% 급등, 도지코인, 시바 이누 (Shiba Inu) 뒤에 숨어</a>

Cryptocurrency

RBLX

SOFI

TWLO

아크 인베스트: 긍정적인 시장 움직임과 분석가의 상향조정에도 코인베이스 주식 $640만 처분

수요일, 캐시 우드의 아크 인베스트가 핀터레스트 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>)의 추가 주식을 구매하는 것으로 눈에 띄는 움직임을 보였다.
핀터레스트의 거래
아크 인베스트의 핀테크 이노베이션 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>)는인기 소셜 미디어 웹사이트이자 메타 플랫폼이 소유한 인스타그램 및 X와 같은 플랫폼의 경쟁사인 핀터레스트의 주식 26,925주를 인수했다. 이 움직임은 핀터레스트의 금융 상황이 복합적인 가운데 이루어졌지만, 최근 <a href="https://www.benzinga.com/news/earnings/24/02/37019165/pinterest-q4-earnings-revenue-miss-eps-beat-monthly-active-users-up-11-and-more">4분기 실적</a> 보고서에서 보여준 유망한 사용자 성장을 바탕으로 한다. 이 거래의 가치는 동일 날 35.28달러의 종가를 바탕으로 하여 949,914달러이다.
아크 인베스트가 핀터레스트에 관심을 보이는 것은 이번이 처음이 아니다. 지난 2월에도 이 투자 기관은 4분기 실적에서의 혼란에도 불구하고 이 회사의 잠재력에 대한 자신감을 증명하기 위해 2,300만달러 이상의 핀터레스트 주식을 구매했다. 최근에 이루어진 이번 구매는 아크 인베스트의 핀터레스트 보유 지분을 더욱 확고히 했다.
기타 중요한 거래들:
아크 인베스트핀테크 이노베이션 ETF에서 트윌리오 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>)의 주식을 팔았다. 이 회사는 또한 게노믹 리볼루션 ETF를 위해 벌브 테라퓨틱스(Verve Therapeutics Inc) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>)와 퍼스널리스(Personalis Inc) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>)의 주식을 구매했다.
넥스트 제너레이션 인터넷(Next Generation Internet) ETF에서는 트윌리오의 주식을 팔고 데이터독(Datadog Inc) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>)의 주식을 샀다.
N/A

Comments

Verve Therapeutics

뉴스

에 대한 최신 뉴스 Verve Therapeutics (NASDAQ:VERV) 주식

목요일, 7월 04, 2024

화요일, 6월 25, 2024

목요일, 6월 13, 2024

화요일, 6월 11, 2024

금요일, 6월 07, 2024

금요일, 4월 05, 2024

목요일, 4월 04, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌